Related by context. All words. (Click for frequent words.) 69 Prolongs Survival 69 essential thrombocythemia ET 67 kidney urologic 67 Demonstrates Significant 67 SUTENT ® 67 Hsp# Inhibitor 66 CYT# potent vascular disrupting 66 Immunomedics Announces 66 Combination REOLYSIN R 66 BrachySil TM 66 Peginterferon alfa 2b 66 Granted Orphan Drug 66 sunitinib Sutent 66 Initiates Clinical Trial 66 Demonstrates Sustained 66 Shows Efficacy 66 Oral Fingolimod 66 thetreatment 65 Shows Promise Against 65 Achieves Primary Endpoint 65 pain palliation 65 Evoltra ® 65 Hormone Refractory Prostate Cancer 65 Tumor Response 65 Renal Cancer 65 Initiate Clinical Trial 65 Receives Orphan Drug Designation 65 Initiates Enrollment 65 AAG geldanamycin analog 65 Xanafide 65 Levels Linked 65 Castration Resistant Prostate Cancer 65 Gets FDA Clearance 65 Antitumor 65 receptor tyrosine kinase inhibitor 65 Presents Preclinical 65 Gleevec Glivec 65 demonstrated antitumor activity 65 Patients Treated With 65 Psoriasis Drug 64 seliciclib CYC# 64 novel emulsion formulation 64 Eribulin 64 ® bortezomib 64 Lymphoid 64 Novel Oral 64 Temodar ® 64 chronic thromboembolic pulmonary 64 HCV Protease Inhibitor 64 Aplidin 64 Completes Patient Enrollment 64 Anti Tumor 64 Adjuvant Treatment 64 HDL Selective Delipidation 64 LungAlert TM 64 histamine dihydrochloride 64 Initiates Clinical 64 Prospective Randomized 64 Meets Primary Endpoint 64 relapsed MM 64 Files IND 64 HDAC Inhibitor 64 Drug Fails 64 Improves Outcomes 64 Bayer HealthCare Onyx Pharmaceuticals 64 Cardiotoxicity 64 Late Breaker 64 Tykerb lapatinib 64 fosbretabulin 64 Amrubicin 64 acetonide FA 64 DNA intercalator 64 Pirfenidone 64 EGS# 64 Reports Preclinical Data 64 Safinamide 64 Pivotal Study 64 Drug Shows Promise 64 Romiplostim 64 Deforolimus 64 evaluating tivozanib 64 Antigen CEA 64 Initiates Phase II 64 Ocrelizumab 64 Immunotherapeutic 64 thalidomide Thalomid 63 Successfully Completes Phase 63 Nicotine Vaccine 63 Subtypes 63 Cystatin C 63 VEGF induced 63 Phase 2b Clinical Trial 63 myelodysplastic myeloproliferative diseases 63 psoriasis Crohn disease 63 Clinical Trial Results 63 Drug Candidate 63 antiangiogenic agent 63 brivanib 63 Teva Provides Update 63 follicular Non Hodgkin 63 refractory colorectal cancer 63 humanized therapeutic 63 Myelofibrosis 63 Orally Active 63 reduce serum phosphate 63 Antitumor Activity 63 Microwave Ablation System 63 Sunesis Pharma 63 MGd 63 Postdoctoral Position 63 polycythemia vera essential thrombocythemia 63 Neuroprotection 63 Anthracycline 63 PHASE III 63 papillary renal cell carcinoma 63 Zemplar Capsules 63 refractory chronic lymphocytic 63 Interferon beta 63 Shows Promising 63 LymphoStat B belimumab 63 Xelox 63 vitro pharmacology 63 preclinical efficacy 63 Celgene Revlimid 63 Pharmacodynamic 63 Bosutinib 63 BRAF inhibitor 63 candidates Azedra TM 63 IAP inhibitor 63 Hedgehog Pathway Inhibitor 63 SinuNase ™ 63 Brentuximab Vedotin SGN 63 Glycosylation 63 Mantle Cell Lymphoma 63 Myelodysplastic Syndromes 63 Pharmacokinetics PK 63 novel VDA molecule 63 Aeolus Pharmaceuticals Announces 63 recurrent glioblastoma multiforme 63 oral picoplatin 62 STRIDE PD 62 p# biomarker 62 progressive metastatic prostate 62 Demonstrates Positive 62 TELINTRA R 62 Bayer Nexavar 62 Submits Response 62 novel immunotherapies 62 BAL# [002] 62 mediated inhibition 62 Cites Positive 62 ara C 62 Triapine 62 Ceflatonin R 62 RhuDex TM 62 SNT MC# 62 NPM1 mutation 62 Aridol TM 62 Severe Sepsis 62 Aurora Kinase 62 Kinase Inhibitor 62 lexidronam injection 62 Receives CE Marking 62 echocardiographic parameters 62 cisplatin gemcitabine 62 metastatic colorectal 62 vapreotide acetate 62 IN PATIENTS WITH 62 MAGE A3 ASCI 62 LSE ASM 62 Pertuzumab 62 GVAX ® 62 tolerability pharmacokinetics 62 Combo Therapy 62 Second Pivotal Phase 62 Renal Cell Carcinoma RCC 62 Phase 2a Trial 62 Improves Survival 62 Lung Cancer Drug 62 PI3K/Akt pathway inhibitor 62 Initiates Phase 2b 62 liver resection surgeries 62 accumulate preferentially 62 SPRYCEL ® 62 Submits NDA 62 biliary tract cancer 62 Romidepsin 62 Vidaza azacitidine 62 Pivotal Phase III 62 Warfarin Coumadin 62 Trandolapril 62 Afatinib 62 fusion enhancers 62 motesanib diphosphate 62 Kinoid 62 targeted antifolate 62 CTAP# Capsules 62 Archexin 62 CYP#A# CYP#D# 62 Randomized Trials 62 nasal decolonization 62 Long Term Efficacy 62 Preclinical Efficacy 62 ixabepilone 62 Ellence 62 Vidofludimus 62 Nilotinib 62 Sapacitabine 62 lymphoma multiple myeloma 62 Submits IND 62 Announces Poster Presentations 62 CONBRIZA 62 Troxatyl 62 small molecule tyrosine 62 Node Positive 62 Crofelemer budesonide foam 62 ThermoDox ® clinical 62 Arzerra ofatumumab 62 Tesmilifene 62 hepatocellular carcinoma liver 62 lung pancreatic 62 EGFR HER2 62 Patients Receiving 62 #-# Full Text 62 lumiliximab 62 hypereosinophilic syndrome 62 cortisol synthesis 62 Preclinical Models 62 Hodgkin lymphoma HL 62 Systemic Sclerosis 62 chronic idiopathic thrombocytopenic purpura 62 Dose Escalation 62 First Patient Enrolled 62 anti PlGF 62 Vitaxin 62 Clinical Trial Data 62 GW# [003] 62 deCODE ProstateCancer TM 62 CHAMPION PCI 62 Mg Usa 62 pancreatic islet cell 62 MGN# 62 Hematological Malignancies 61 intravascular hemolysis 61 Temsirolimus 61 INSPIRE Trial Phase III 61 R lenalidomide 61 cardio renal 61 Fulvestrant 61 Monoclonal antibody 61 Squalamine 61 Amgen Neulasta R 61 histone deacetylase inhibitor 61 Begins Dosing 61 TNFerade TM 61 metastatic renal cell 61 Drug Prevents 61 Uterine Cancer 61 Estybon ™ 61 BRAF mutant 61 Data Suggest 61 CCR9 antagonist 61 Trovax 61 Granulocyte Colony Stimulating Factor 61 Novel Inhibitor 61 relapsing remitting MS RRMS 61 multiple myeloma MM 61 Gastrointestinal Stromal Tumors 61 Azacitidine 61 Denufosol 61 Announcement acc 61 Preclinical Study 61 Fludara ® 61 Kamada AAT 61 paclitaxel poliglumex 61 patients receiving myelosuppressive 61 INTEGRILIN R eptifibatide Injection 61 ® lenalidomide 61 recurrent metastatic 61 BCIRG 61 Ferinject R 61 Investigational Drug 61 Prestara 61 Lupus Drug 61 Microplasmin 61 include ColorectAlert TM 61 Relapsing Remitting Multiple Sclerosis 61 p# inhibitor 61 brivaracetam 61 mGluR2 NAM 61 RoACTEMRA 61 unresectable tumors 61 Nexavar sorafenib 61 achieved CCyR 61 Naive Patients 61 TO AVOID PREGNANCY WHILE 61 Telik Announces 61 Panzem ® 61 Chronic Lymphocytic Leukemia CLL 61 alpha GAL 61 Degarelix 61 Glufosfamide 61 CHMP Opinion 61 Localized Prostate Cancer 61 Pazopanib 61 vinca alkaloid 61 lung esophageal 61 Carfilzomib 61 completely resected 61 Activity Assay 61 metaglidasen 61 Phase IIa Clinical Trial 61 Alfacell proprietary ribonuclease 61 Amgen Neulasta ® 61 Golimumab 61 metastatic gastric 61 sargramostim 61 Estrogen Receptor 61 liposomal formulation 61 Intravitreal 61 Diabetic Foot Ulcer 61 antimitotic 61 Chronic lymphocytic leukemia CLL 61 Aryplase 61 novel histone deacetylase 61 Yondelis ® 61 inhaled AAT 61 Tyrosine Kinase Inhibitor 61 CINQUIL 61 cathepsin K inhibitor 61 Telatinib 61 Study Evaluating 61 R Bortezomib 61 FDA Okays 61 Cutaneous T 61 topoisomerase II inhibitor 61 PSMA ADC 61 Phase III Clinical Trial 61 sapacitabine CYC# 61 Phase III multicenter 61 FUSILEV enhances 61 Therapeutic Competitors companiesandmarkets.com adEgemonye 61 Pfizer Camptosar 61 Randomized Clinical Trials 61 Vitrasert R 61 Eluting Stent 61 Phase #b/#a clinical 61 Initiates Clinical Trials 61 investigational humanized monoclonal antibody 61 Zarnestra 61 Phase Ib II 61 CYP#A# substrate 61 Immunosuppression 61 G#DT 61 Orphan Status 61 Synta Announces 61 Recurrent Breast Cancer 61 phase IIb trial 61 PF # [002] 61 Prednisone Against Refractory 61 Lymphocytic 61 ZACTIMA 61 lenalidomide Revlimid 61 Advanced Melanoma 61 Hematological 61 JAK2 Inhibitor 61 Investigational Treatment 61 #:#-#,# CrossRef Medline [002] 61 Neoadjuvant Chemotherapy 61 Follicular Lymphoma 61 dyslipidemia hypertension diabetes 61 LHRH receptor positive 61 VANTAS ® 61 PLX STROKE targeting 61 Mucosal 61 Multicenter Phase 61 sunitinib malate 61 Presents Positive Preclinical 61 Protease Inhibitor 61 Roche Xeloda 61 Progenitor Cells 61 Amgen denosumab 61 HepaMate 61 mTOR mammalian target 61 Muraglitazar 61 Initiate Phase II 61 Relapsing Multiple Sclerosis 61 Anticancer Drug 61 Parathyroid Hormone 61 Known hypersensitivity 61 ADVEXIN therapy 61 Epratuzumab 61 SPP# Rasilez 61 Lilly Alimta 61 Arzerra TM 61 smoldering multiple myeloma 61 Malignant Glioma 61 initiated Phase Ib 61 dual endothelin receptor antagonist 61 Recombinant Human 61 Clinical Outcome 61 Adjuvant Therapy 61 Novel Therapeutic 61 immunotherapeutic approaches 61 gemcitabine Gemzar ® 61 abnormal p# 61 metastatic pancreatic 61 metastatic renal 61 hematological parameters 61 CTEPH 61 adjuvant cisplatin 61 Multiple Ascending Dose 60 gefitinib Iressa 60 omacetaxine mepesuccinate 60 CRMD# 60 epoetin zeta 60 Stage IIB 60 Hematologic 60 deCODE AF TM 60 Troxatyl TM 60 Phase III Trial 60 FDA APPROVES 60 SSc 60 TroVax ® 60 Randomized Phase II 60 PHRM 60 P#X# antagonist 60 Removab 60 UPLYSO 60 mitogen activated ERK kinase 60 Renal Artery 60 Aflibercept 60 pediatric acute lymphoblastic 60 Phase Ib Clinical Trial 60 BEXXAR Therapeutic Regimen 60 HCV NS5B polymerase 60 Zybrestat 60 refractory metastatic 60 Liposomal 60 Zalypsis 60 Tramiprosate ALZHEMED TM 60 serum biomarker 60 Abiraterone Acetate 60 bladder ovarian 60 myelofibrosis polycythemia vera 60 treating neuropathic pain 60 Decitabine 60 lymphoproliferative disorders 60 hereditary emphysema 60 Relapsed Multiple Myeloma 60 Fingolimod 60 Vaccine Immunology 60 fludarabine cyclophosphamide 60 ARRY # 60 protein tyrosine phosphatase 1B 60 Sirolimus Eluting Stent 60 Marketing Authorisation Application 60 advanced metastatic renal 60 taxane refractory 60 PROSTASCINT R 60 Analytical Tool 60 proteasome inhibitor 60 Mg Uk 60 successfully commercialize Iluvien 60 Ambrisentan 60 Survival Benefit 60 Randomized Study 60 Vascugel ® 60 Demonstrates Efficacy 60 Related Mortality 60 Lupus Nephritis 60 Confirmatory Phase 60 Patient Treated 60 TLR antagonist 60 Treatment Shows Promise 60 Active Ulcerative Colitis 60 immunotherapeutic vaccine 60 Treating Chronic 60 stage IIIb IV 60 Amgen Vectibix 60 Nonalcoholic Steatohepatitis 60 Ibritumomab Tiuxetan 60 rasagiline tablets 60 Cloretazine 60 constipation OIC 60 Sipuleucel T 60 Newly Diagnosed Multiple Myeloma 60 vinorelbine tartrate 60 Virulizin ® 60 BCG refractory 60 Onconase 60 NS5B polymerase 60 Ceflatonin 60 M# rationally 60 polycythemia vera PV 60 Apoptotic 60 novel therapeutic antibodies 60 Synthetic Peptide 60 Test Detects 60 ThermoDox R 60 relapsed acute lymphoblastic 60 BrachySil ™ 60 lucinactant 60 Plaque Psoriasis 60 Enzastaurin 60 Oral Mucositis 60 Initiates Phase III 60 Antisoma plc 60 Onyx Pharmaceuticals Announces 60 Histologic 60 Epidermal Growth Factor Receptor 60 Val HeFT 60 CD# antibody [002] 60 Angiox ® 60 Vascugel 60 drug Treanda 60 Antiviral Therapy 60 tyrosine kinase inhibitor TKI 60 investigational therapies 60 Subgroup Analysis 60 Daclizumab 60 Cholesterol Lowering Drug 60 Demonstrate Significant 60 agalsidase alfa 60 humanised antibody 60 riociguat 60 benign prostatic hyperplasia enlarged 60 induced macular edema 60 adalimumab Humira 60 Tasigna prolongs 60 Systemic Lupus Erythematosus SLE 60 By JENNIFER LEARN 60 Phase 1b clinical trials 60 Apolipoprotein B 60 drug figitumumab 60 antibody MAb 60 Relapsed Refractory 60 LymphoStat B TM 60 Vandetanib 60 Calcium Acetate 60 gallium nitrate 60 SNT-MC#/idebenone 60 demonstrated clinically meaningful 60 HuMax EGFr 60 NeuroSTAT ® 60 miconazole Lauriad ® 60 mitoxantrone plus 60 malignant ascites 60 stem cell engraftment 60 antiproliferative effects 60 somatostatin analog 60 Risk Stratification 60 Phase 1a clinical 60 Ixempra 60 haematologic 60 Thalomid ® 60 Pivotal Phase 60 Slows Progression 60 Gleevec imatinib mesylate 60 HBeAg + 60 ACTOS ® 60 patientswith 60 Cimzia TM 60 novel oral anticoagulant 60 Diffuse Large B 60 MKC# MKC# PP 60 HER2 Positive Breast Cancer 60 Showed Significant 60 steroid refractory 60 refractory acute lymphoblastic 60 Provectus Pharmaceuticals specializes 60 HIF PHI 60 pan HDAC inhibitor 60 AA Amyloidosis 60 microtubule inhibitor 60 Novel Antibiotic 60 cytidine nucleoside analog 60 targeted radiotherapeutic 60 Fibroblast 60 dirucotide MBP# 60 leukemia multiple myeloma 60 Cloretazine ® 60 HER2 ErbB2 60 Fondaparinux 60 MoxDuo ® 60 Randomized Controlled Trials 60 Interferon Gamma 60 Renal Cell Cancer 60 Progressive Multifocal Leukoencephalopathy 60 Velcade bortezomib 60 lymphoid malignancies 60 Bucindolol 60 haematological cancers 60 neoadjuvant treatment 60 5 fluorouracil leucovorin 60 ZK EPO 60 Fludarabine 60 Gastric Cancer 60 Salix Pharmaceuticals Announces 60 Elagolix 60 Chronic Renal Failure 60 AFREZZA TM 60 baseline LDH 60 Acute Ischemic Stroke 60 Adult Stem Cell Therapy 60 Xcytrin R 60 Prodarsan R 60 benign neoplasms 60 Confirms Efficacy 60 Vertex hepatitis C 60 Raloxifene STAR 60 Rasilamlo 60 Certican 60 FDA Approvals 60 chronic eosinophilic leukemia 60 Upregulation 60 Novartis Afinitor 60 hematological indications 60 gastrointestinal stromal tumors GISTs 60 investigational immunotherapy 60 PrevOnco 60 commercialize deforolimus 60 BR.# 60 MELAS 60 HuMax TAC 60 Signaling Pathway 60 ALN HPN 60 Is Well Tolerated 60 isoform selective 60 denileukin diftitox 60 drotrecogin alfa activated 60 Bayer Onyx 60 Initiate Phase 60 Lenalidomide 60 NAVISTAR R 59 HepDirect prodrug 59 Erythropoietic 59 Roche Herceptin 59 GlaxoSmithKline Tykerb 59 Appears Safe 59 Clinical Guideline 59 TRANSFORMS 59 Desvenlafaxine Succinate 59 Hedgehog Pathway 59 Gentium Announces 59 immune modulating 59 Recurrent Glioblastoma 59 Kit CD# positive 59 Prostate AdenoCarcinoma Treatment 59 epoetin alpha 59 International SMI SYNN 59 Natalizumab 59 Febuxostat 59 YONDELIS 59 VNP#M 59 orally administered inhibitor 59 NSABP B 59 IMiDs ® compound 59 Adjuvant Chemotherapy 59 GVAX Pancreas Vaccine 59 IG HCR ;) CO 59 Cloretazine R 59 midstage clinical 59 Disease Modifying 59 Idiopathic Pulmonary Fibrosis 59 Cancer Incidence Mortality 59 potently inhibit 59 pancreatic prostate 59 Topoisomerase II 59 Oral Calcitonin 59 Myoblast 59 bavituximab monotherapy trial 59 Glioblastoma Multiforme 59 RSR# 59 multicenter Phase II 59 2 inhibitor CYT# 59 coronary stent merged 59 FDA Approves Novel 59 Mycophenolate Mofetil 59 opioid induced constipation OIC 59 Stage IIIA 59 Advanced Renal Cell 59 REMINYL ® 59 Chemoradiation 59 skeletal metastases 59 Olmesartan 59 Heart Transplant Recipients 59 AS# amonafide L malate 59 number NCT# ClinicalTrials.gov 59 Friedreich Ataxia FRDA 59 trastuzumab DM1 T DM1 59 interferon gamma 1b 59 Vascular Wrap TM 59 NuroPro PD 59 tumor necrosis 59 Expanded Indication 59 MKC# MT 59 chronic myocardial ischemia 59 Gamunex C 59 Gleevec resistant 59 farletuzumab 59 hyperphenylalaninemia HPA due 59 including eniluracil ADH 59 ELIQUIS 59 Platinum Chromium 59 Cloretazine VNP#M 59 PDE# inhibitors 59 Pivotal Clinical Trial 59 receptor antagonism 59 ABLYNX 59 chemotherapeutic regimen 59 Adenomas 59 metastatic malignant 59 Candesartan 59 melphalan prednisone 59 Bazedoxifene 59 adjuvant colon cancer 59 Laryngeal Cancer 59 anti angiogenic agents 59 Ovarian Cancers 59 Interferon beta 1a 59 YONDELIS R 59 Tigecycline 59 RENAL 59 Epirubicin 59 Therapy Improves 59 gastrointestinal stromal 59 Silodosin 59 psoriatic arthritis PsA 59 pan histone deacetylase 59 Li Fraumeni Syndrome 59 Rigel R# 59 Pivotal Trial 59 Potelligent Technology 59 Corgentin 59 PANVAC VF 59 Olaparib 59 Optimer Pharma 59 CLL SLL 59 Galectin 3 59 Targretin capsules 59 personalized cellular immunotherapy 59 APPRAISE 59 recurrent NSCLC 59 ovarian prostate 59 Evoltra 59 ISTODAX ® 59 BIOV 59 ImmuKnow R 59 ACTEMRA TM 59 Refractory Angina 59 Modrenal 59 Chronic lymphocytic leukemia 59 Glatiramer acetate 59 liposomal doxorubicin 59 FOLOTYN ® 59 secondary hyperparathyroidism 59 Oral Laquinimod 59 Randomized Evaluation 59 antibiofilm 59 Pemphigus Vulgaris 59 Pruvel 59 oral antiplatelet therapy 59 Gene Linked 59 BRIM3 59 hormone receptor negative 59 ABL1 59 Randomized Double blind 59 CALGB # [002] 59 oncolytic virus therapies 59 MediGene focuses 59 Files Investigational 59 unfavorable cytogenetics 59 clinicopathological features 59 Cypher Sirolimus 59 Catena ® 59 gastric carcinoma 59 hoFH 59 Annamycin 59 triggers apoptosis programmed 59 Left Ventricular Dysfunction 59 IMA# 59 pharmacodynamic profiles 59 Fabry Disease 59 nilotinib Tasigna 59 Phase 2a Clinical Trial 59 cisplatin resistant 59 Randomized Phase 59 haematologic malignancies 59 beta 1a 59 Bronchiectasis 59 pharmacogenomic translational research 59 Metastatic Renal Cell Carcinoma 59 SIR Spheres 59 Angiolix 59 unresectable liver cancer 59 recurrent malignant glioma 59 Transdermal Delivery 59 dasatinib Sprycel 59 Accelerated Partial Breast Irradiation 59 ASONEP TM 59 Onrigin 59 IMPACT DCM 59 biostatistical analysis 59 Newly Diagnosed Patients 59 ON #.Na 59 Interferon Beta 59 R Saizen R 59 MYLOTARG 59 Protein Kinase C 59 Acute myelogenous leukemia 59 assessing T DM1 59 Crit Rev 59 Biological Therapy 59 OvaRex R 59 transthyretin TTR mediated amyloidosis 59 PERSEUS 59 Prospective Multicenter 59 Echocardiographic 59 histone deacetylase HDAC inhibitor 59 ticagrelor Brilinta 59 HMG CoA reductase inhibitors 59 Therapy Shows Promise 59 HeFH 59 Kidney Transplant Patients 59 alpha1 antitrypsin deficiency 59 Sudhir Agrawal D.Phil 59 generation purine nucleoside 59 vidofludimus 59 SPL# Gel vaginal microbicide 59 TYSABRI natalizumab 59 Zavesca r 59 Reduces Mortality 59 Vicriviroc 59 etanercept Enbrel 59 Computed Tomographic 59 lymphomas leukemias 59 Renal Cell Carcinoma 59 KIACTA ™ 59 follicular lymphoma FL 59 Zorbtive TM 59 TNF Tumor Necrosis Factor 59 Sanvar R 59 cause mesothelioma asbestosis 59 Prognostic significance 59 Carbidopa Levodopa 59 MCSP respectively 59 prospective multicenter study 59 TORISEL TM 59 pretransplant 59 Factor VIIa 59 docetaxel Taxotere ® 59 haematological 59 KL4 Surfactant 59 GENASIS 59 mouse xenograft models 59 Exelixis XL# 59 Diazyme 59 Lubiprostone 59 DNA methylation markers 59 Hematological Cancers 59 Anticancer Agent 59 Vion Pharmaceuticals 59 ANN INTERN MED 59 AVN# Phase 59 HGS ETR1 mapatumumab 59 Receives Marketing Authorization 59 chimeric monoclonal antibody 59 selective modulator 59 Alkeran 59 myocardial infarction ventricular fibrillation 59 EGFR tyrosine kinase inhibitor 59 azilsartan medoxomil 59 Stereotactic Body Radiation Therapy 59 5 HT4 59 monoclonal antibody IgG1 Mab 59 acyclovir Lauriad R 59 Vernakalant 59 Orphan Designation 59 phase Ib 59 Carotid endarterectomy 59 ST Segment Elevation 59 Arno Therapeutics 59 AMPK activators 59 potently inhibited 59 Inflammatory Markers 59 CT Angiography 59 pretreatment serum 59 Peripheral Arterial 59 Virologic 59 tramiprosate Alzhemed TM 59 negative allosteric modulator 59 rALLy 59 Hepatotoxicity 59 tiuxetan 59 Pooled Analysis 59 Homeostasis 59 intra abdominal infections 59 Catheter Associated 59 Neuvenge 59 Angiotensin Converting Enzyme 59 LAB CGRP 59 Hepatocellular Carcinoma HCC 59 APTIVUS R 59 RhuDex R 59 Demonstrates Statistically Significant 59 NeuroMove TM 59 EGFr humanized monoclonal antibody 59 MelaFind R 59 IMiDs ® 59 Kahalalide F 59 Gemzar gemcitabine 58 SOM# 58 Squamous 58 PNP inhibitor 58 MDS AML 58 Rheumatoid Arthritis Patients 58 Adjunctive Therapy 58 rALLy clinical trial 58 trastuzumab DM1 58 AVASTIN 58 CLARITY study 58 compound AEZS 58 ACUITY trial 58 AGGRASTAT R tirofiban hydrochloride 58 Antiviral Activity 58 XYOTAX TM 58 Omacetaxine 58 evaluating T DM1 58 Clinical Trial Evaluating 58 PRESEPT study 58 Tarceva TM 58 histologic subtype 58 Raptiva R 58 Pediatric Oncology Branch 58 REG2 58 Neurol 58 Trofex 58 Molecular Cancer 58 Curaxin CBLC# 58 DASISION 58 Initiated Phase 58 Quinamed 58 selective agonists 58 ruxolitinib 58 Deferiprone 58 Investigational Drugs 58 DCVax R 58 orally inhaled migraine 58 Inhaled Nitric Oxide 58 myeloid metaplasia 58 Phase III AFFIRM 58 AVOREN 58 Therapeutic Vaccine 58 pharmacodynamic parameters 58 Edge STudy 58 TheraSphere R 58 Dementia Related Psychosis 58 GERD migraine headaches 58 Vertebral Fractures 58 Moxifloxacin 58 Panzem R NCD 58 autologous peripheral 58 histologies 58 Targeted Therapies 58 Phase Ib IIa 58 MEK Inhibitor 58 NICE Recommends 58 Embolic Protection 58 Bacteremia 58 B Cell Lymphoma 58 AKT inhibitor 58 potent inducer 58 Radioimmunotherapy 58 RANK Ligand inhibitor 58 HER2 Positive 58 Hyperlipidemia 58 mesangial 58 OVATURE 58 estrogen receptor beta agonist 58 SIX RO ROG 58 myeloproliferative diseases 58 alpha 2A adrenergic 58 psoriasis rheumatoid arthritis 58 Insegia 58 Histopathological 58 Arch Neurol 58 Pegloticase 58 Breast Cancer Assay 58 huN# DM1 58 ICON7 58 evaluating REVLIMID 58 angiogenesis inhibition 58 histone deacetylase HDAC 58 Pyridorin 58 5 HT2A 58 Microalbuminuria 58 CLL8 58 NOVARTIS